Therapeutic decisions following progression on first-line treatment with endocrine therapy and CDK4/6 inhibition should be based, whenever this is possible, on a genomic analysis of the patient’s tumor or circulating tumor DNA (ctDNA). This evidence concerns the gene CDK4 and neoplasm.